Pneumococcal vaccination in developing countries.

Saved in:
Bibliographic Details
Title: Pneumococcal vaccination in developing countries.
Authors: Levine, Orin S., O'Brien, Katherine L., Knoll, Maria, Adegbola, Richard A., Black, Steven, Cherian, Thomas, Dagan, Ron, Goldblatt, David, Grange, Adenike, Greenwood, Brian, Hennessy, Tom, Klugman, Keith P., Madhi, Shabir A., Mulholland, Kim, Nohynek, Hanna, Santosham, Mathuram, Saha, Samir K., Scott, J. Anthony, Sow, Samba, Cutts, Felicity
Source: Lancet. 6/10/2006, Vol. 367 Issue 9526, p1880-1882. 3p. 1 Color Photograph.
Subjects: Pneumococcal vaccines, Preventive pediatrics, Preventive medicine, Pneumococcal pneumonia, Meningitis vaccines, Sepsis vaccines, Clinical trials, International cooperation, Vaccination
Geographic Terms: Gambia
Abstract: The article reports on the global health risk presented by pneumococcal disease. 1.6 million people, of whom 1 million are children, die of pneumococcal pneumonia, meningitis, and sepsis each year. People with HIV infection have a risk increased by 20-40%. Antibiotic resistance can make the diseases difficult to treat. Clinical trials show that pneumococcal conjugate vaccines improve child survival. A trial in Gambia showed treatment to reduce mortality from all causes by 16% and to provide from 65-83% protection from infection, depending on HIV status. The article calls for affordable vaccines to be made available to developing countries, where their administration can be worked into the preexisting vaccine system.
Database: Psychology and Behavioral Sciences Collection
Description
Abstract:The article reports on the global health risk presented by pneumococcal disease. 1.6 million people, of whom 1 million are children, die of pneumococcal pneumonia, meningitis, and sepsis each year. People with HIV infection have a risk increased by 20-40%. Antibiotic resistance can make the diseases difficult to treat. Clinical trials show that pneumococcal conjugate vaccines improve child survival. A trial in Gambia showed treatment to reduce mortality from all causes by 16% and to provide from 65-83% protection from infection, depending on HIV status. The article calls for affordable vaccines to be made available to developing countries, where their administration can be worked into the preexisting vaccine system.
ISSN:01406736
DOI:10.1016/S0140-6736(06)68703-5